Rafferty Asset Management
BCAX

Rafferty Asset Management’s Bicara Therapeutics BCAX Stock Holding History

Rafferty Asset Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$905K Sell
30,480
-7,523
-20% -$168K ﹤0.01% 804
2026
Q1 		$756K Sell
38,003
-21,816
-36% -$376K ﹤0.01% 828
2025
Q4 		$1.01M Buy
+59,819
New +$1.02M ﹤0.01% 799

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rafferty Asset Management's BCAX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Bicara Therapeutics (BCAX) stake by 20% in Q2 2026, selling an estimated $168K and leaving 30,480 shares worth $905K. The position accounts for ﹤0.01% of the portfolio, ranked #804.

Rafferty Asset Management first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.01M in Q4 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Rafferty Asset Management held 30,480 shares of Bicara Therapeutics worth $905K as of Q2 2026.
  • Rafferty Asset Management sold 7,523 Bicara Therapeutics shares in Q2 2026, an estimated $168K.
  • Bicara Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #804 holding.
  • Rafferty Asset Management first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rafferty Asset Management's Bicara Therapeutics position peaked at $1.01M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.